These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12073633)

  • 1. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Colorectal cancer].
    Ito K; Kato T
    Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):270-7. PubMed ID: 12073633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
    Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.
    Hung GU; Shiau YC; Tsai SC; Chao TH; Ho YJ; Kao CH
    Anticancer Res; 2001; 21(2B):1375-8. PubMed ID: 11396217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
    Wiering B; Ruers TJ; Oyen WJ
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
    Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
    Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
    Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
    Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical application of positron emission tomography to colorectal cancer management.
    Arulampalam TH; Costa DC; Bomanji JB; Ell PJ
    Q J Nucl Med; 2001 Sep; 45(3):215-30. PubMed ID: 11788814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
    Pelosi E; Deandreis D
    Eur J Surg Oncol; 2007 Feb; 33(1):1-6. PubMed ID: 17126522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography in colorectal cancer.
    Flamen P
    Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography and colorectal cancer.
    Arulampalam TH; Costa DC; Loizidou M; Visvikis D; Ell PJ; Taylor I
    Br J Surg; 2001 Feb; 88(2):176-89. PubMed ID: 11167864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging recurrent metastatic colorectal carcinoma with PET.
    Delbeke D; Vitola JV; Sandler MP; Arildsen RC; Powers TA; Wright JK; Chapman WC; Pinson CW
    J Nucl Med; 1997 Aug; 38(8):1196-201. PubMed ID: 9255148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer.
    Strasberg SM; Dehdashti F
    J Surg Oncol; 2010 Dec; 102(8):955-9. PubMed ID: 21165998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
    Valk PE; Abella-Columna E; Haseman MK; Pounds TR; Tesar RD; Myers RW; Greiss HB; Hofer GA
    Arch Surg; 1999 May; 134(5):503-11; discussion 511-3. PubMed ID: 10323422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the role of FDG PET-CT for potentially operable metastatic colorectal cancer.
    Culverwell AD; Chowdhury FU; Scarsbrook AF
    Abdom Imaging; 2012 Dec; 37(6):1021-31. PubMed ID: 22371087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of patients with liver metastases from colorectal cancer for locally ablative treatment with laser induced thermotherapy. Impact of PET with 18F-fluorodeoxyglucose on therapeutic decisions.
    Amthauer H; Denecke T; Hildebrandt B; Rühl R; Miersch A; Nicolaou A; Ruf J; Plotkin M; Hänninen EL; Stroszczynski C; Gutberlet M; Langrehr J; Riess H; Ricke J
    Nuklearmedizin; 2006; 45(4):177-84. PubMed ID: 16964344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer.
    Huebner RH; Park KC; Shepherd JE; Schwimmer J; Czernin J; Phelps ME; Gambhir SS
    J Nucl Med; 2000 Jul; 41(7):1177-89. PubMed ID: 10914907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET for the pre-operative evaluation of colorectal liver metastases.
    Arulampalam TH; Francis DL; Visvikis D; Taylor I; Ell PJ
    Eur J Surg Oncol; 2004 Apr; 30(3):286-91. PubMed ID: 15028310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.